Rodriguez, Javier
Castañón, Eduardo
Perez-Gracia, Jose Luis
Rodriguez, Inmaculada
Viudez, Antonio
Alfaro, Carlos
Oñate, Carmen
Perez, Guiomar
Rotellar, Fernando
Inogés, Susana
López-Diaz de Cerio, Ascensión
Resano, Leyre
Ponz-Sarvise, Mariano
Rodriguez-Ruiz, Maria E.
Chopitea, Ana
Vera, Ruth
Melero, Ignacio
Funding for this research was provided by:
Fundación BBVA
Instituto de Salud Carlos III (TRA007 and EC10-113)
Article History
Received: 30 April 2018
Accepted: 6 September 2018
First Online: 29 September 2018
Ethics approval and consent to participate
: All patients provided informed consent approved as the clinical trial protocol by the CEIC of the local Government of Navarra (CEIC). The IMPD dossier and the clinical trial protocol were approved by Agencia Española del Medicamento y productos sanitarios (AEMPS). This was an investigator initiated clinical trial sponsored by UNAV and fulfills requirements by spanish law (<i>Real Decreto</i> 1090/2015).
: Informed consent included consent for publication and patients are coded and made anonym according to good clinical practices.
: IM served as an advisor to BMS, Roche, AstraZeneca, Genmab, Alligator, Tusk, Bioncotech, Merck-Serono.IM receives research grants from BMS, Roche and Alligator.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.